123 related articles for article (PubMed ID: 37824367)
21. SPOP promotes CDCA5 degradation to regulate prostate cancer progression via the AKT pathway.
Luo Z; Wang J; Zhu Y; Sun X; He C; Cai M; Ma J; Wang Y; Han S
Neoplasia; 2021 Oct; 23(10):1037-1047. PubMed ID: 34509929
[TBL] [Abstract][Full Text] [Related]
22. [Identification of speckle type BTB/POZ protein mutation regulated key metabolic pathways by cell based proteomics and metabolomics].
Yan M; Liu J; Xia T; Xu G; Piao H
Se Pu; 2019 Aug; 37(8):887-896. PubMed ID: 31642260
[TBL] [Abstract][Full Text] [Related]
23. Genetic Profiling of African American Patients With Prostatic Adenocarcinoma Metastatic to the Lymph Nodes: A Pilot Study.
Bidot S; Yin J; Zhou P; Zhang L; Deeb KK; Smith G; Hill CE; Xiu J; Bilen MA; Case KB; Tinsley M; Carthon B; Harik LR
Arch Pathol Lab Med; 2024 Mar; 148(3):310-317. PubMed ID: 37327205
[TBL] [Abstract][Full Text] [Related]
24. GLI3 Is Stabilized by SPOP Mutations and Promotes Castration Resistance via Functional Cooperation with Androgen Receptor in Prostate Cancer.
Burleson M; Deng JJ; Qin T; Duong TM; Yan Y; Gu X; Das D; Easley A; Liss MA; Yew PR; Bedolla R; Kumar AP; Huang TH; Zou Y; Chen Y; Chen CL; Huang H; Sun LZ; Boyer TG
Mol Cancer Res; 2022 Jan; 20(1):62-76. PubMed ID: 34610962
[TBL] [Abstract][Full Text] [Related]
25. BTB/POZ domain of speckle-type POZ protein (SPOP) confers proapoptotic function in HeLa cells.
Byun B; Tak H; Joe CO
Biofactors; 2007; 31(3-4):165-9. PubMed ID: 18997279
[TBL] [Abstract][Full Text] [Related]
26. Phosphorylation-dependent regulation of SPOP by LIMK2 promotes castration-resistant prostate cancer.
Nikhil K; Haymour HS; Kamra M; Shah K
Br J Cancer; 2021 Mar; 124(5):995-1008. PubMed ID: 33311589
[TBL] [Abstract][Full Text] [Related]
27. ELK3 destabilization by speckle-type POZ protein suppresses prostate cancer progression and docetaxel resistance.
Lee CJ; Lee H; Kim SR; Nam SB; Lee GE; Yang KE; Lee GJ; Chun SH; Kang HC; Lee JY; Lee HS; Cho SJ; Cho YY
Cell Death Dis; 2024 Apr; 15(4):274. PubMed ID: 38632244
[TBL] [Abstract][Full Text] [Related]
28. SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence.
Hernández-Llodrà S; Segalés L; Juanpere N; Marta Lorenzo T; Salido M; Nonell L; David López T; Rodríguez-Vida A; Bellmunt J; Fumadó L; Cecchini L; Lloreta-Trull J
Prostate; 2021 Dec; 81(16):1267-1277. PubMed ID: 34533858
[TBL] [Abstract][Full Text] [Related]
29. SPOP-mutant prostate cancer: Translating fundamental biology into patient care.
Bernasocchi T; Theurillat JP
Cancer Lett; 2022 Mar; 529():11-18. PubMed ID: 34974131
[TBL] [Abstract][Full Text] [Related]
30. Snail promotes prostate cancer migration by facilitating SPOP ubiquitination and degradation.
Lv W; Huan M; Yang W; Gao Y; Wang K; Xu S; Zhang M; Ma J; Wang X; Chen Y; Li L
Biochem Biophys Res Commun; 2020 Aug; 529(3):799-804. PubMed ID: 32736710
[TBL] [Abstract][Full Text] [Related]
31. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.
Guo Z; Yang X; Sun F; Jiang R; Linn DE; Chen H; Chen H; Kong X; Melamed J; Tepper CG; Kung HJ; Brodie AM; Edwards J; Qiu Y
Cancer Res; 2009 Mar; 69(6):2305-13. PubMed ID: 19244107
[TBL] [Abstract][Full Text] [Related]
32. ERK1/2 inhibits Cullin 3/SPOP-mediated PrLZ ubiquitination and degradation to modulate prostate cancer progression.
Fan Y; Hou T; Dan W; Zhu Y; Liu B; Wei Y; Wang Z; Gao Y; Zeng J; Li L
Cell Death Differ; 2022 Aug; 29(8):1611-1624. PubMed ID: 35194188
[TBL] [Abstract][Full Text] [Related]
33. Dysregulation of INF2-mediated mitochondrial fission in SPOP-mutated prostate cancer.
Jin X; Wang J; Gao K; Zhang P; Yao L; Tang Y; Tang L; Ma J; Xiao J; Zhang E; Zhu J; Zhang B; Zhao SM; Li Y; Ren S; Huang H; Yu L; Wang C
PLoS Genet; 2017 Apr; 13(4):e1006748. PubMed ID: 28448495
[TBL] [Abstract][Full Text] [Related]
34. Krüppel-like factor 8 is a novel androgen receptor co-activator in human prostate cancer.
He HJ; Gu XF; Xu WH; Yang DJ; Wang XM; Su Y
Acta Pharmacol Sin; 2013 Feb; 34(2):282-8. PubMed ID: 23023312
[TBL] [Abstract][Full Text] [Related]
35. The diverse roles of SPOP in prostate cancer and kidney cancer.
Wang Z; Song Y; Ye M; Dai X; Zhu X; Wei W
Nat Rev Urol; 2020 Jun; 17(6):339-350. PubMed ID: 32355326
[TBL] [Abstract][Full Text] [Related]
36. TBLR1 as an androgen receptor (AR) coactivator selectively activates AR target genes to inhibit prostate cancer growth.
Daniels G; Li Y; Gellert LL; Zhou A; Melamed J; Wu X; Zhang X; Zhang D; Meruelo D; Logan SK; Basch R; Lee P
Endocr Relat Cancer; 2014 Feb; 21(1):127-42. PubMed ID: 24243687
[TBL] [Abstract][Full Text] [Related]
37. The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer.
Yan Y; Ma J; Wang D; Lin D; Pang X; Wang S; Zhao Y; Shi L; Xue H; Pan Y; Zhang J; Wahlestedt C; Giles FJ; Chen Y; Gleave ME; Collins CC; Ye D; Wang Y; Huang H
EMBO Mol Med; 2019 Nov; 11(11):e10659. PubMed ID: 31559706
[TBL] [Abstract][Full Text] [Related]
38. The emerging role of speckle-type POZ protein (SPOP) in cancer development.
Mani RS
Drug Discov Today; 2014 Sep; 19(9):1498-502. PubMed ID: 25058385
[TBL] [Abstract][Full Text] [Related]
39. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
Li R; Wheeler T; Dai H; Frolov A; Thompson T; Ayala G
Am J Surg Pathol; 2004 Jul; 28(7):928-34. PubMed ID: 15223964
[TBL] [Abstract][Full Text] [Related]
40. SPOP promotes ATF2 ubiquitination and degradation to suppress prostate cancer progression.
Ma J; Chang K; Peng J; Shi Q; Gan H; Gao K; Feng K; Xu F; Zhang H; Dai B; Zhu Y; Shi G; Shen Y; Zhu Y; Qin X; Li Y; Zhang P; Ye D; Wang C
J Exp Clin Cancer Res; 2018 Jul; 37(1):145. PubMed ID: 29996942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
